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arm
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h
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to
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in
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on
cise
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e
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C
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of
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U
n
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of
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ical
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C
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IU
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d
n
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en
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H
exose
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fam
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h
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m
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ositolcotran
sporter
tran
sporters
S385
SLC
6
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fam
ily
S385
M
on
oam
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ily
S386
G
A
BA
tran
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G
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fam
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fam
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fam
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co-tran
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In
tro
d
u
ctio
n
In
orderto
allow
clarity
an
d
con
sisten
cy
in
ph
arm
acology,th
ere
is
a
n
eed
for
a
com
preh
en
sive
organ
isation
an
d
presen
tation
of
th
e
targets
ofdrugs.Th
is
is
th
e
ph
ilosoph
y
ofth
e
IU
PH
A
R
/BPS
G
uide
to
PH
A
R
M
A
C
O
LO
G
Y
presen
ted
on
th
e
on
lin
e
free
access
database
(h
ttp://w
w
w
.guidetoph
arm
acology.org/).
Th
is
database
is
sup-
ported
by
th
e
British
Ph
arm
acological
Society
(BPS),th
e
In
tern
a-
tion
al
U
n
ion
of
Basic
an
d
C
lin
ical
Ph
arm
acology
(IU
PH
A
R
),
th
e
U
n
iversity
ofEdin
burgh
an
d
previously
th
e
W
ellcom
e
Trust.D
ata
in
cluded
in
th
e
G
uide
to
PH
A
R
M
A
C
O
LO
G
Y
are
derived
in
large
part
from
in
teraction
s
w
ith
th
e
subcom
m
ittees
of
th
e
N
om
en
cla-
ture
C
om
m
ittee
of
th
e
In
tern
ation
al
U
n
ion
of
Basic
an
d
C
lin
ical
Ph
arm
acology
(N
C
-IU
PH
A
R
).
A
m
ajor
in
fluen
ce
on
th
e
develop-
m
en
t
ofth
e
database
w
as
Ton
y
H
arm
ar
(1951-2014),w
h
o
w
orked
w
ith
a
passion
to
establish
th
e
curators
as
a
team
of
h
igh
ly
in
-
form
ed
an
d
in
form
ative
in
dividuals,w
ith
a
focus
on
h
igh
-quality
data
in
put,
en
surin
g
a
suitably
validated
dataset.
Th
e
Editors
of
th
e
C
on
cise
G
uide
h
ave
com
piled
th
e
in
dividualrecords,in
con
-
cert
w
ith
th
e
team
of
C
urators,
draw
in
g
on
th
e
expert
kn
ow
l-
edge
ofth
ese
lattersubcom
m
ittees.Th
e
tables
allow
an
in
dication
of
th
e
status
of
th
e
n
om
en
clature
for
th
e
group
of
targets
listed,
usually
previously
publish
ed
in
Ph
arm
acological
R
eview
s.
In
th
e
absen
ce
of
an
establish
ed
subcom
m
ittee,
advice
from
several
prom
in
en
t,
in
depen
den
t
experts
h
as
gen
erally
been
obtain
ed
to
produce
an
auth
oritative
con
sen
sus
on
n
om
en
clature,
w
h
ich
at-
tem
pts
to
fit
in
w
ith
in
th
e
gen
eral
guidelin
es
from
N
C
-IU
PH
A
R
.
Th
is
curren
t
edition
,
th
e
C
on
cise
G
uide
to
PH
A
R
M
A
C
O
LO
G
Y
2017/18,is
th
e
latest
sn
apsh
ot
of
th
e
database
in
prin
t
form
,fol-
low
in
g
on
from
th
e
C
on
cise
G
uide
to
PH
A
R
M
A
C
O
LO
G
Y
2015/16.
It
con
tain
s
data
draw
n
from
th
e
on
lin
e
database
as
a
rapid
overview
of
th
e
m
ajor
ph
arm
acological
targets.
Th
us,
th
ere
are
m
an
y
few
er
targets
presen
ted
in
th
e
C
on
cise
G
uide
com
pared
to
th
e
on
lin
e
database.
Th
e
priority
for
in
clusion
in
th
e
C
on
cise
G
uide
is
th
e
presen
ce
of
quan
titative
ph
arm
acological
data.
Th
is
m
ean
s
th
atoften
orph
an
fam
ily
m
em
bers
are
n
otpresen
ted
in
th
e
C
on
cise
G
uide,alth
ough
structuralin
form
ation
isavailable
on
th
e
on
lin
e
database.Th
e
organ
isation
ofth
e
data
is
tabular(w
h
ere
ap-
propriate)
w
ith
a
stan
dardised
form
at,w
h
ere
possible
on
a
sin
gle
page,in
ten
ded
to
aid
un
derstan
din
g
of,an
d
com
parison
w
ith
in
,a
particulartargetgroup.Th
e
C
on
cise
G
uide
isin
ten
ded
asan
in
itial
resource,w
ith
lin
ks
to
addition
alreview
s
an
d
resources
forgreater
depth
an
d
in
form
ation
.Ph
arm
acologicalan
d
structuraldata
focus
prim
arily
on
h
um
an
gen
e
products,w
h
erever
possible,w
ith
lin
ks
to
H
G
N
C
gen
e
n
om
en
clature
an
d
U
n
iProt
ID
s.
In
a
few
cases,
w
h
ere
data
from
h
um
an
protein
s
are
lim
ited,
data
from
oth
er
species
are
in
dicated.
Ph
arm
acological
tools
listed
are
prioritised
on
th
e
basisofselectivity
an
d
availability.Th
atis,agen
ts(agon
ists,
an
tagon
ists,
in
h
ibitors,
activators,
etc.)
are
in
cluded
w
h
ere
th
ey
are
both
available
(by
don
ation
or
from
com
m
ercialsources,n
ow
or
in
th
e
n
ear
future)
A
N
D
th
e
m
ost
selective.Th
e
C
on
cise
G
uide
isdivided
in
to
n
in
e
section
s,w
h
ich
com
prise
ph
arm
acologicaltar-
gets
of
sim
ilar
structure/fun
ction
.
Th
ese
are
G
protein
-coupled
receptors,ligan
d-gated
ion
ch
an
n
els,voltage-gated
ion
ch
an
n
els,
oth
er
ion
ch
an
n
els,
catalytic
receptors,
n
uclear
h
orm
on
e
recep-
tors,
en
zym
es,
tran
sporters
an
d
oth
er
protein
targets.
W
e
h
ope
th
at
th
e
C
on
cise
G
uide
w
ill
provide
for
research
ers,teach
ers
an
d
studen
ts
a
state-of-th
e
art
source
ofaccurate,curated
in
form
ation
on
th
e
backgroun
d
to
th
eirw
ork
th
atth
ey
w
illuse
in
th
e
In
troduc-
tion
s
to
th
eir
R
esearch
Papers
or
R
eview
s,
or
in
supportin
g
th
eir
teach
in
g
an
d
studies.
W
e
recom
m
en
d
th
at
an
y
citation
s
to
in
-
form
ation
in
th
e
C
on
cise
G
uide
are
presen
ted
in
th
e
follow
in
g
form
at:
A
lexan
der
SPH
etal.(2017).Th
e
C
on
cise
G
uide
to
PH
A
R
M
A
C
O
L-
O
G
Y
2017/18:O
verview
.Br
J
Ph
arm
acol174:S1–S16.
In
th
isoverview
are
listed
protein
targetsofph
arm
acologicalin
ter-
est,
w
h
ich
are
n
ot
G
protein
-coupled
receptors,
ligan
d-gated
ion
ch
an
n
els,voltage-gated
ion
ch
an
n
els,ion
ch
an
n
els,n
uclear
h
or-
m
on
e
receptors,catalytic
receptors,tran
sporters
or
en
zym
es.
A
ck
n
o
w
led
g
em
en
ts
W
e
are
extrem
ely
gratefulto
th
e
British
Ph
arm
acologicalSociety
an
d
th
e
In
tern
ation
alU
n
ion
ofBasic
an
d
C
lin
icalPh
arm
acology,for
fin
an
cialsupport
ofth
e
w
ebsite
an
d
for
advice
from
th
e
N
C
-IU
PH
A
R
subcom
m
ittees.
W
e
th
an
k
th
e
U
n
iversity
of
Edin
burgh
,w
h
o
h
ost
th
e
w
w
w
.guidetoph
arm
acology.org
w
ebsite.
Previously,th
e
In
tern
ation
alU
n
ion
of
Basic
an
d
C
lin
icalPh
arm
acology
an
d
th
e
W
ellcom
e
Trust
(099156/Z/12/Z])
also
supported
th
e
in
itiation
an
d
expan
sion
ofth
e
database.W
e
are
also
trem
en
dously
gratefulto
th
e
lon
g
list
ofcollaborators
from
N
C
-IU
PH
A
R
subcom
m
ittees
an
d
beyon
d,w
h
o
h
ave
assisted
in
th
e
con
struction
of
th
e
C
on
cise
G
uide
to
PH
A
R
M
A
C
O
LO
G
Y
2017/18
an
d
th
e
on
lin
e
database
w
w
w
.G
uideToPH
A
R
M
A
C
O
LO
G
Y.org.
Furth
er,w
e
w
ish
to
th
an
k
Ton
iW
igglesw
orth
for
h
er
assistan
ce
in
th
e
co-ordin
ation
of
correspon
den
ce
w
ith
th
ese
collaborators.
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O
ther
Protein
Targets
Fam
ily
stru
ctu
re
S6
A
dipon
ectin
receptors
–
B-celllym
ph
om
a
2
(Bcl-2)
protein
fam
ily
S7
Blood
coagulation
com
pon
en
ts
–
Brom
odom
ain
-con
tain
in
g
protein
s
S7
N
on
-en
zym
atic
BR
D
con
tain
in
g
protein
s
S8
C
arrier
protein
s
S9
C
D
m
olecules
–
C
h
rom
atin
-in
teractin
g
tran
scription
alrepressors
S10
M
eth
yllysin
e
reader
protein
s
–
C
ircadian
clock
protein
s
–
C
laudin
s
–
EF-h
an
d
dom
ain
con
tain
in
g
S11
Fatty
acid-bin
din
g
protein
s
–
G
-alph
a
fam
ily
G
(q)
subfam
ily
–
H
eat
sh
ock
protein
s
–
Im
m
un
oglobulin
s
–
In
h
ibitors
of
apoptosis
(IA
P)
protein
fam
ily
–
K
elch
-like
protein
s
–
K
in
esin
s
–
Leucin
e-rich
repeat
protein
s
–
Lym
ph
ocyte
an
tigen
s
–
M
itoch
on
drial-associated
protein
s
–
M
yosin
bin
din
g
protein
s
–
N
on
-catalytic
pattern
recogn
ition
receptors
–
A
bsen
t
in
m
elan
om
a
(A
IM
)-like
receptors
(A
LR
s)
–
C
-type
lectin
-like
receptors
(C
LR
s)
–
O
th
er
pattern
recogn
ition
receptors
S12
N
otch
receptors
–
Pen
taxin
s
–
Serum
pen
taxin
s
S13
R
egulators
of
G
protein
Sign
alin
g
(R
G
S)
protein
s
S14
R
4
fam
ily
–
R
epulsive
guidan
ce
m
olecules
–
R
eticulon
s
an
d
associated
protein
s
–
R
ibosom
alfactors
S14
Sigm
a
receptors
S15
Tubulin
s
–
Tum
our-associated
protein
s
–
W
D
repeat-con
tain
in
g
protein
s
A
diponectin
receptors
O
th
er
protein
targets→
A
dipon
ectin
receptors
O
verview
:
A
dipon
ectin
receptors
(p
ro
visio
n
al
n
o
m
en
-
clatu
re,
EN
SFM
00500000270960)
respon
d
to
th
e
30
kD
a
com
plem
en
t-related
protein
h
orm
on
e
adipon
ectin
(also
kn
ow
n
as
A
D
IPO
Q
:
adipocyte,
C
1q
an
d
collagen
dom
ain
-con
tain
in
g
protein
;
A
C
R
P30,
adipose
m
ost
abun
dan
t
gen
e
tran
script
1;
apM
-1;gelatin
-bin
din
g
protein
:
Q
15848)
origin
ally
clon
ed
from
adipocytes
[49].
A
lth
ough
sequen
ce
data
suggest
7TM
dom
ain
s,
im
m
un
ologicaleviden
ce
in
dicates
th
at,con
trary
to
typical7TM
topology,th
e
carboxylterm
in
us
is
extracellular,w
h
ile
th
e
am
in
o
term
in
us
is
in
tracellular
[90].
Sign
allin
g
th
rough
th
ese
receptors
appearsto
avoid
G
protein
s;m
odellin
g
based
on
th
e
crystalstruc-
tures
of
th
e
adipon
ectin
receptors
suggested
ceram
idase
acivity,
w
h
ich
w
ould
m
ake
th
ese
th
e
first
in
a
n
ew
fam
ily
of
catalytic
re-
ceptors
[93].
N
om
enclature
Adipo1
receptor
Adipo2
receptor
H
G
N
C
,U
niProt
AD
IPO
R1,Q
96A54
AD
IPO
R2,Q
86V24
Rank
order
ofpotency
globular
adiponectin
(AD
IPO
Q
,Q
15848)
>
adiponectin
(AD
IPO
Q
,Q
15848)
globular
adiponectin
(AD
IPO
Q
,Q
15848)
=
adiponectin
(AD
IPO
Q
,Q
15848)
C
o
m
m
en
ts:T-C
adh
erin
(C
D
H
13,P55290)
h
as
also
been
suggested
to
be
a
receptor
for
(h
exam
eric)
adipon
ectin
[33].
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Fu
rth
er
read
in
g
o
n
A
d
ip
o
n
ectin
recep
to
rs
Fism
an
EZ
et
al.
(2014)
A
dipon
ectin
:
a
m
an
ifold
th
erapeutic
target
for
m
etabolic
syn
drom
e,
dia-
betes,an
d
coron
ary
disease?
C
ardiovasc
D
iabetol13
:103
[PM
ID
:24957699]
M
atsuda
M
et
al.
(2014)
R
oles
of
adipon
ectin
an
d
oxidative
stress
in
obesity-associated
m
etabolic
an
d
cardiovascular
diseases.
Rev
Endocr
M
etab
D
isord
15
:1-10
[PM
ID
:24026768]
R
uan
H
etal.(2016)
A
dipon
ectin
sign
alin
g
an
d
fun
ction
in
in
sulin
target
tissues.
JM
olC
ellBiol8
:
101-9
[PM
ID
:26993044]
W
an
g
Y
et
al.
(2017)
C
ardiovascular
A
dipon
ectin
R
esistan
ce:
Th
e
C
riticalR
ole
of
A
dipon
ectin
R
e-
ceptor
M
odification
.
Trends
EndocrinolM
etab
28
:519-530
[PM
ID
:28473178]
Zh
ao
L
et
al.
(2014)
A
dipon
ectin
an
d
in
sulin
cross
talk:
th
e
m
icrovascular
con
n
ection
.
Trends
C
ardiovasc
M
ed
24
:319-24
[PM
ID
:25220977]
Blood
coagulation
com
ponents
O
th
er
protein
targets→
Blood
coagulation
com
pon
en
ts
O
verview
:C
oagulation
as
a
process
is
in
terpreted
as
a
m
ech
an
ism
for
reducin
g
excessive
blood
loss
th
rough
th
e
gen
eration
ofa
gel-like
clot
localto
th
e
site
ofin
jury.Th
e
process
in
volves
th
e
activation
,
adh
esion
(see
In
tegrin
s),degran
ulation
an
d
aggregation
ofplatelets,as
w
ellas
protein
s
circulatin
g
in
th
e
plasm
a.Th
e
coagulation
cascade
in
volves
m
ultiple
protein
s
bein
g
con
verted
to
m
ore
active
form
s
from
less
active
precursors,typically
th
rough
proteolysis
(see
Proteases).Listed
h
ere
are
th
e
com
pon
en
ts
of
th
e
coagulation
cascade
targetted
by
agen
ts
in
curren
t
clin
icalusage.
N
om
enclature
coagulation
factor
V
coagulation
factor
VIII
serpin
fam
ily
C
m
em
ber
1
H
G
N
C
,U
niProt
F5,P12259
F8,P00451
SERPIN
C1,P01008
Selective
activators
–
–
heparin
(pK
d
7.8)
[26],fondaparinux
(pK
d
7.5)
[62],dalteparin
[32],danaparoid
[16,56],enoxaparin
[19],tinzaparin
[20]
Selective
inhibitors
drotrecogin
alfa
[36,37]
drotrecogin
alfa
[36,37]
–
Fu
rth
er
read
in
g
o
n
B
lo
o
d
co
ag
u
latio
n
co
m
p
o
n
en
ts
A
sterm
ark
J.
(2015)
FV
III
in
h
ibitors:
path
ogen
esis
an
d
avoidan
ce.
Blood
125
:
2045-51
[PM
ID
:25712994]
G
irolam
iA
et
al.
(2017)
N
ew
clottin
g
disorders
th
at
cast
n
ew
ligh
t
on
blood
coagulation
an
d
m
ay
play
a
role
in
clin
icalpractice.
JT
hrom
b
T
hrom
bolysis
44
:71-75
[PM
ID
:28251495]
R
an
a
K
et
al.
(2016)
Blood
flow
an
d
m
ass
tran
sfer
regulation
of
coagulation
.
Blood
Rev
30
:
357-68
[PM
ID
:27133256]
Searchable
database:http://w
w
w.guidetopharm
acology.org/index.jsp
Blood
coagulation
com
ponents
S7
FullC
ontents
ofC
onciseG
uide:http://onlinelibrary.w
iley.com
/doi/10.1111/bph.13882/full
S.P.H.Alexanderetal.The
Concise
Guide
to
PHARM
ACOLOGY
2017/18:Overview.British
JournalofPharm
acology
(2017)174,S1–S16
N
on-enzym
atic
BRD
containing
proteins
O
th
er
protein
targets→
Brom
odom
ain
-con
tain
in
g
protein
s→
N
on
-en
zym
atic
BR
D
con
tain
in
g
protein
s
O
verview
:
Brom
odom
ain
s
bin
d
protein
s
w
ith
acetylated
lysin
e
residues,
such
as
h
iston
es,
to
regulate
gen
e
tran
scription
.
Listed
h
erein
are
exam
ples
of
brom
o
dom
ain
-con
tain
in
g
protein
s
for
w
h
ich
sufficien
t
ph
arm
acology
exists.
N
om
enclature
brom
odom
ain
adjacent
to
zinc
finger
dom
ain
2A
brom
odom
ain
adjacent
to
zinc
finger
dom
ain
2B
C
REB
binding
protein
polybrom
o
1
SW
I/SN
F
related,m
atrix
associated,
actin
dependent
regulator
of
chrom
atin,subfam
ily
a,m
em
ber
4
H
G
N
C
,U
niProt
BAZ2A,Q
9U
IF9
BAZ2B,Q
9U
IF8
CREBBP,Q
92793
PBRM
1,Q
86U
86
SM
ARCA4,P51532
Selective
inhibitors
G
SK2801
(pK
d
6.6)
[73]
G
SK2801
(pK
d
6.9)
[73]
I-C
BP112
(pK
d
6.8)
[72]
PFI-3
(pK
d
7.3)
[79]
PFI-3
(pK
d
7.1)
[79]
Fu
rth
er
read
in
g
o
n
N
o
n
-en
zym
atic
B
R
D
co
n
tain
in
g
p
ro
tein
s
Bran
d
M
et
al.
(2015)
Sm
all
m
olecule
in
h
ibitors
of
brom
odom
ain
-acetyl-lysin
e
in
teraction
s.
A
C
S
C
hem
.Biol.10
:22-39
[PM
ID
:25549280]
Fujisaw
a
T
et
al.
(2017)
Fun
ction
s
of
brom
odom
ain
-con
tain
in
g
protein
s
an
d
th
eir
roles
in
h
om
e-
ostasis
an
d
can
cer
N
atRev
M
olC
ellBiol18
:246-262
[PM
ID
:28053347]
N
ich
olas
D
A
et
al.
(2017)
BET
brom
odom
ain
protein
s
an
d
epigen
etic
regulation
of
in
flam
m
a-
tion
:
im
plication
s
for
type
2
diabetes
an
d
breast
can
cer.
C
ell
M
ol
Life
Sci
74
:
231-243
[PM
ID
:27491296]
Th
eodoulou
N
H
etal.(2016)C
lin
icalprogress
an
d
ph
arm
acology
ofsm
allm
olecule
brom
odom
ain
in
h
ibitors.
C
urr
O
pin
C
hem
Biol33
:58-66
[PM
ID
:27295577]
Th
eodoulou
N
H
et
al.
(2016)
Progress
in
th
e
D
evelopm
en
t
of
n
on
-BET
Brom
odom
ain
C
h
em
ical
Probes.C
hem
M
edC
hem
11
:477-87
[PM
ID
:26749027]
C
arrier
proteins
O
th
er
protein
targets→
C
arrier
protein
s
O
verview
:
Tran
sth
yretin
(TTR
)
is
a
h
om
o-tetram
eric
protein
w
h
ich
tran
sports
th
yroxin
e
in
th
e
plasm
a
an
d
cerebrospin
alfluid
an
d
retin
ol
(vitam
in
A
)
in
th
e
plasm
a.
M
an
y
disease
causin
g
m
utation
s
in
th
e
protein
h
ave
been
reported,
m
an
y
of
w
h
ich
cause
com
plex
dissociation
an
d
protein
m
is-assem
bly
an
d
depo-
sition
of
toxic
aggregates
am
yloid
fibril
form
ation
[63].
Th
ese
am
yloidogen
ic
m
utan
ts
are
lin
ked
to
th
e
developm
en
t
ofpath
o-
logicalam
yloidoses,in
cludin
g
fam
ilialam
yloid
polyn
europath
y
(FA
P)
[4,14],fam
ilialam
yloid
cardiom
yopath
y
(FA
C
)
[34],am
y-
loidotic
vitreous
opacities,carpaltun
n
elsyn
drom
e
[54]an
d
oth
-
ers.
In
old
age,
n
on
-m
utated
TTR
can
also
form
path
ological
am
yloid
fibrils
[88].
Ph
arm
acological
in
terven
tion
to
reduce
or
preven
t
TTR
dissociation
is
bein
g
pursued
as
a
th
eapeutic
strat-
egy.
To
date
on
e
sm
all
m
olecule
kin
etic
stabilisin
g
m
olecule
(tafam
idis)
h
as
been
approved
for
FA
P,an
d
is
bein
g
evaluated
in
clin
icaltrials
for
oth
er
TTR
am
yloidoses.
N
om
enclature
transthyretin
H
G
N
C
,U
niProt
TTR,P02766
C
om
m
on
abreviation
TTR
Searchable
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w
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Fu
rth
er
read
in
g
o
n
C
arrier
p
ro
tein
s
A
lsh
eh
ri
B
et
al.
(2015)
Th
e
diversity
of
m
ech
an
ism
s
in
fluen
ced
by
tran
sth
yretin
in
n
euro-
biology:
developm
en
t,
disease
an
d
en
docrin
e
disruption
.
J
N
euroendocrinol
27
:
303-23
[PM
ID
:25737004]
D
elliere
S
et
al.
(2017)
Is
tran
sth
yretin
a
good
m
arker
of
n
utrition
alstatus?
C
lin
N
utr
36
:
364-370
[PM
ID
:27381508]
G
alan
tN
Jetal.(2017)Tran
sth
yretin
am
yloidosis:an
un
der-recogn
ized
n
europath
y
an
d
cardiom
y-
opath
y.
C
lin
Sci(Lond)131
:395-409
[PM
ID
:28213611]
C
D
m
olecules
O
th
er
protein
targets→
C
D
m
olecules
O
verview
:C
luster
ofdifferen
tiation
refers
to
an
attem
pt
to
catalogue
system
atically
a
series
ofover
300
cell-surface
protein
s
associated
w
ith
im
m
un
otypin
g.M
an
y
m
em
bers
ofth
e
group
h
ave
iden
tified
fun
ction
s
as
en
zym
es
(for
exam
ple,see
C
D
73
ecto-5’-n
ucleotidase)
or
receptors
(for
exam
ple,see
C
D
41
in
tegrin
,alph
a
2b
subun
it).
M
an
y
C
D
s
are
targetted
for
th
erapeutic
gain
usin
g
an
tibodies
for
th
e
treatm
en
t
of
proliferative
disorders.
A
full
listin
g
of
all
th
e
C
lusters
of
D
ifferen
tiation
is
n
ot
possible
in
th
e
G
uide
to
PH
A
R
M
A
C
O
LO
G
Y;
listed
h
erein
are
selected
m
em
bers
of
th
e
fam
ily
targetted
for
th
erapeutic
gain
.
N
om
enclature
C
D
2
C
D
3e
C
D
20
(m
em
brane-spanning
4-dom
ains,subfam
ily
A,
m
em
ber
1)
C
D
33
C
D
52
H
G
N
C
,U
niProt
CD
2,P06729
CD
3E,P07766
M
S4A1,P11836
CD
33,P20138
CD
52,P31358
C
om
m
on
abreviation
–
–
–
SIG
LEC
-3
–
Selective
inhibitors
alefacept
(Inhibition)
[17,53]
–
–
–
–
Antibodies
–
catum
axom
ab
(Binding)
[43],m
urom
onab-C
D
3
(Binding)
[25],
otelixizum
ab
(Binding)
[9]
ofatum
um
ab
(Binding)
(pK
d
9.9)
[47],rituxim
ab
(Binding)
(pK
d
8.5)
[75],
ibritum
om
ab
tiuxetan
(Binding),
obinutuzum
ab
(Binding)
[3,66],
tositum
om
ab
(Binding)
lintuzum
ab
(Binding)
(pK
d ∼
10)
[10],
gem
tuzum
ab
ozogam
icin
(Binding)
[7]
alem
tuzum
ab
(Binding)
[24,79]
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N
om
enclature
C
D
80
C
D
86
cytotoxic
T-lym
phocyte-associated
protein
4
(C
D
152)
program
m
ed
celldeath
1
(C
D
279)
C
D
300a
H
G
N
C
,U
niProt
CD
80,P33681
CD
86,P42081
CTLA4,P16410
PD
CD
1,Q
15116
CD
300A,Q
9U
G
N
4
C
om
m
on
abreviation
–
–
C
TLA-4
PD
-1
–
Antibodies
–
–
ipilim
um
ab
(pK
d
>
9)
[28],
trem
elim
um
ab
(pK
d
8.9)
[30]
pem
brolizum
ab
(pK
d ∼
10)
[11],nivolum
ab
(pK
d
9.1)
[28,38,40]
–
C
o
m
m
en
t:Th
e
en
dogen
ous
ligan
dsforh
um
an
PD
-1
are
program
m
ed
celldeath
1
ligan
d
1
(PD
-L1
aka
C
D
274
(C
D
274,Q
9N
ZQ
7))an
d
program
m
ed
celldeath
1
ligan
d
2
(PD
-L2;PD
C
D
1LG
2).Th
ese
ligan
ds
are
cell
surface
peptides,
n
orm
ally
in
volved
in
im
m
un
e
system
regulation
.
Expression
of
PD
-1
by
can
cer
cells
in
duces
im
m
un
e
toleran
ce
an
d
evasion
of
im
m
un
e
system
attack.
A
n
ti-PD
-1
m
on
oclon
al
an
tibodies
are
used
to
in
duce
im
m
un
e
ch
eckpoin
t
blockade
as
a
th
erapeutic
in
terven
tion
in
can
cer,effectively
re-establish
in
g
im
m
un
e
vigilan
ce.
pem
brolizum
ab
w
as
th
e
first
an
ti-PD
-1
an
tibody
to
be
approved
by
th
e
U
S
FD
A
.
Fu
rth
er
read
in
g
o
n
C
D
m
o
lecu
les
G
abiusH
Jetal.(2015)Th
e
glycobiology
ofth
e
C
D
system
:a
diction
ary
fortran
slatin
g
m
arkerdesig-
n
ation
s
in
to
glycan
/lectin
structure
an
d
fun
ction
.Trends
Biochem
Sci40
:360-76
[PM
ID
:25981696]
M
ethyllysine
reader
proteins
O
th
er
protein
targets→
C
h
rom
atin
-in
teractin
g
tran
scription
alrepressors→
M
eth
yllysin
e
reader
protein
s
O
verview
:M
eth
yllysin
e
reader
protein
s
bin
d
to
m
eth
ylated
protein
s,such
as
h
iston
es,allow
in
g
regulation
of
gen
e
expression
.
N
om
enclature
l(3)m
bt-like
3
(D
rosophila)
H
G
N
C
,U
niProt
L3M
BTL3,Q
96JM
7
Selective
agonists
U
N
C
1215
[35]
Fu
rth
er
read
in
g
o
n
M
eth
yllysin
e
read
er
p
ro
tein
s
Liu
K
et
al.
(2015)
Epigen
etic
targets
an
d
drug
discovery
Part
2:
H
iston
e
dem
eth
ylation
an
d
D
N
A
m
eth
ylation
.
Pharm
acol.T
her.151
:121-40
[PM
ID
:25857453]
M
ilosevich
N
et
al.
(2016)
C
h
em
ical
In
h
ibitors
of
Epigen
etic
M
eth
yllysin
e
R
eader
Protein
s.
Bio-
chem
istry
55
:1570-83
[PM
ID
:26650180]
Sadakierska-C
h
udy
A
et
al.
(2015)
A
com
preh
en
sive
view
of
th
e
epigen
etic
lan
dscape
part
I:D
N
A
m
eth
ylation
,passive
an
d
active
D
N
A
dem
eth
ylation
path
w
ays
an
d
h
iston
e
varian
ts.
N
eurotox
Res
27
:84-97
[PM
ID
:25362550]
Teske
K
A
etal.(2017)
M
eth
yllysin
e
bin
din
g
dom
ain
s:Structuralin
sigh
t
an
d
sm
allm
olecule
probe
developm
en
t.
Eur
JM
ed
C
hem
136
:14-35
[PM
ID
:28478342]
Zah
n
ow
C
A
et
al.
(2016)
In
h
ibitors
of
D
N
A
M
eth
ylation
,
H
iston
e
D
eacetylation
,
an
d
H
iston
e
D
em
eth
ylation
:
A
Perfect
C
om
bin
ation
for
C
an
cer
Th
erapy.
A
dv
C
ancer
Res
130
:
55-111
[PM
ID
:27037751]
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Fatty
acid-binding
proteins
O
th
er
protein
targets→
Fatty
acid-bin
din
g
protein
s
O
verview
:Fatty
acid-bin
din
g
protein
sare
low
m
olecularw
eigh
t
(100-130
aa)ch
aperon
es
forlon
g
ch
ain
fatty
acids,fatty
acylC
oA
esters,
eicosan
oids,
retin
ols,
retin
oic
acids
an
d
related
m
etabo-
lites
an
d
are
usually
regarded
as
bein
g
respon
sible
for
allow
in
g
th
e
oth
erw
ise
h
ydroph
obic
ligan
ds
to
be
m
obile
in
aqueous
m
e-
dia.
Th
ese
bin
din
g
protein
s
m
ay
perform
fun
ction
s
extracellu-
larly
(e.g.
in
plasm
a)
or
tran
sport
th
ese
agen
ts;
to
th
e
n
ucleus
to
in
teractw
ith
n
uclear
receptors
(prin
cipally
PPA
R
s
an
d
retin
oic
acid
receptors
[70])
or
for
in
teraction
w
ith
m
etabolic
en
zym
es.
A
lth
ough
sequen
ce
h
om
ology
is
lim
ited,
crystallograph
ic
stud-
ies
suggest
con
served
3D
structures
across
th
e
group
of
bin
din
g
protein
s.
N
om
enclature
fatty
acid
binding
protein
1
fatty
acid
binding
protein
2
fatty
acid
binding
protein
3
fatty
acid
binding
protein
4
H
G
N
C
,U
niProt
FABP1,P07148
FABP2,P12104
FABP3,P05413
FABP4,P15090
Rank
order
of
potency
stearic
acid,oleic
acid
>
palm
itic
acid,linoleic
acid
>
arachidonic
acid,α
-linolenic
acid
[67]
stearic
acid
>
palm
itic
acid,oleic
acid
>
linoleic
acid
>
arachidonic
acid,
α
-linolenic
acid
[67]
stearic
acid,oleic
acid,palm
itic
acid
>
linoleic
acid,α
-linolenic
acid,
arachidonic
acid
[67]
oleic
acid,palm
itic
acid,
stearic
acid,linoleic
acid
>
α
-linolenic
acid,arachidonic
acid
[67]
Inhibitors
fenofibrate
(pK
i 7.6)
[12]–
Rat,
fenofibric
acid
(pK
i 6.5)
[12]–
Rat,
H
TS01037
(pK
i 5.1)
[30]–
M
ouse
–
–
–
Selective
inhibitors
–
–
–
H
M
50316
(pK
i >
9)
[46]
C
om
m
ents
A
broader
substrate
specificity
than
other
FABPs,binding
tw
o
fatty
acids
per
protein
[82].
C
rystalstructure
ofthe
rat
FABP2
[69].
C
rystalstructure
ofthe
hum
an
FABP3
[91].
–
N
om
enclature
fatty
acid
binding
protein
5
fatty
acid
binding
protein
6
fatty
acid
binding
protein
7
peripheralm
yelin
protein
2
fatty
acid
binding
protein
9
fatty
acid
binding
protein
12
H
G
N
C
,U
niProt
FABP5,Q
01469
FABP6,P51161
FABP7,O
15540
PM
P2,P02689
FABP9,Q
0Z7S8
FABP12,A6N
FH
5
C
om
m
ents
C
rystalstructure
ofthe
hum
an
FABP5
[31].
Able
to
transport
bile
acids
[95].
C
rystalstructure
ofthe
hum
an
FABP7
[5].
In
silico
m
odelling
suggests
that
PM
P2/FABP8
can
bind
both
fatty
acids
and
cholesterol[50].
–
–
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N
om
enclature
retinolbinding
protein
1
retinolbinding
protein
2
retinolbinding
protein
3
retinolbinding
protein
4
retinolbinding
protein
5
retinolbinding
protein
7
H
G
N
C
,U
niProt
RBP1,P09455
RBP2,P50120
RBP3,P10745
RBP4,P02753
RBP5,P82980
RBP7,Q
96R05
Rank
order
of
potency
–
stearic
acid
>
palm
itic
acid,oleic
acid,
linoleic
acid,
α
-linolenic
acid,
arachidonic
acid
[68]
–
–
–
–
Inhibitors
–
–
–
A1120
(pIC
50
7.8)
[86]
–
–
N
om
enclature
retinaldehyde
binding
protein
1
cellular
retinoic
acid
binding
protein
1
cellular
retinoic
acid
binding
protein
2
H
G
N
C
,U
niProt
RLBP1,P12271
CRABP1,P29762
CRABP2,P29373
Rank
order
ofpotency
11-cis-retinal,11-cis-retinol>
9-cis-retinal,
13-cis-retinal,13-cis-retinol,all-trans-retinal,
retinol[15]
tretinoin
>
alitretinoin
stearic
acid
>
palm
itic
acid,oleic
acid,linoleic
acid,
α
-linolenic
acid,arachidonic
acid
[68]
–
C
o
m
m
en
ts:A
lth
ough
n
ot
tested
at
allFA
BPs,BM
S309403
exh
ibits
h
igh
affin
ity
for
FA
BP4
(pIC
50
8.8)
com
pared
to
FA
BP3
or
FA
BP5
(pIC
50
<
6.6)
[21,81].H
TS01037
is
reported
to
in
terfere
w
ith
FA
BP4
action
[30].
Ibuprofen
displays
som
e
selectivity
for
FA
BP4
(pIC
50
5.5)
relative
to
FA
BP3
(pIC
50
3.5)
an
d
FA
BP5
(pIC
50
3.8)
[48].
Fen
ofibric
acid
displays
som
e
selectivity
for
FA
BP5
(pIC
50
5.5)
relative
to
FA
BP3
(pIC
50
4.5)
an
d
FA
BP4
(pIC
50
4.6)
[48].M
ultiple
pseudogen
es
for
th
e
FA
BPs
h
ave
been
iden
tified
in
th
e
h
um
an
gen
om
e.
Fu
rth
er
read
in
g
o
n
Fatty
acid
-b
in
d
in
g
p
ro
tein
s
G
ajda
A
M
et
al.
(2015)
En
terocyte
fatty
acid-bin
din
g
protein
s
(FA
BPs):
differen
t
fun
ction
s
of
liver
an
d
in
testin
al
FA
BPs
in
th
e
in
testin
e.
Prostaglandins
Leukot.
Essent.
Fatty
A
cids
93
:
9-16
[PM
ID
:25458898]
G
latz
JF.
(2015)
Lipids
an
d
lipid
bin
din
g
protein
s:
a
perfect
m
atch
.
Prostaglandins
Leukot.
Essent.
Fatty
A
cids
93
:45-9
[PM
ID
:25154384]
H
otam
isligil
G
S
et
al.
(2015)
M
etabolic
fun
ction
s
of
FA
BPs-m
ech
an
ism
s
an
d
th
erapeutic
im
plica-
tion
s.N
atRev
Endocrinol11
:592-605
[PM
ID
:26260145]
M
atsum
ata
M
et
al.
(2016)
Fatty
acid
bin
din
g
protein
s
an
d
th
e
n
ervous
system
:
Th
eir
im
pact
on
m
en
talcon
dition
s.
N
eurosci.Res.102
:47-55
[PM
ID
:25205626]
O
sum
iT
etal.(2016)
H
eart
lipid
droplets
an
d
lipid
droplet-bin
din
g
protein
s:Bioch
em
istry,ph
ysi-
ology,an
d
path
ology.
Exp
C
ellRes
340
:198-204
[PM
ID
:26524506]
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N
otch
receptors
O
th
er
protein
targets→
N
otch
receptors
O
verview
:
Th
e
can
on
ocal
N
otch
sign
allin
g
path
w
ay
h
as
four
type
I
tran
sm
em
bran
e
N
otch
receptors
(N
otch
1-4)
an
d
five
lig-
an
ds(D
LL1,2
an
d
3,an
d
Jagged
1-2).Each
m
em
berofth
ish
igh
ly
con
served
receptor
fam
ily
plays
a
un
ique
role
in
cell-fate
deter-
m
in
ation
durin
g
em
bryogen
esis,
differen
tiation
,
tissue
pattern
-
in
g,
proliferation
an
d
cell
death
[2].
A
s
th
e
N
otch
ligan
ds
are
also
m
em
bran
e
boun
d,
cells
h
ave
to
be
in
close
proxim
ity
for
receptor-ligan
d
in
teraction
s
to
occur.
C
leavage
of
th
e
in
tracel-
lular
dom
ain
(IC
D
)
of
activated
N
otch
receptors
by
γ-secretase
is
required
for
dow
n
stream
sign
allin
g
an
d
N
otch
-in
duced
tran
-
scription
al
m
odulation
[18,
57,
71,
89].
Th
is
is
w
h
y
γ-secretase
in
h
ibitors
can
be
used
to
dow
n
regulate
N
otch
sign
allin
g
an
d
explain
s
th
eir
an
ti-can
cer
action
.
O
n
e
such
sm
all
m
olecule
is
R
O
4929097
[47],
alth
ough
developm
en
t
of
th
is
com
poun
d
h
as
been
term
in
ated
follow
in
g
an
un
successfulPh
ase
II
sin
gle
agen
t
clin
icaltrialin
m
etastatic
colorectalcan
cer
[78].
A
berran
t
N
otch
sign
allin
g
is
im
plicated
in
a
n
um
ber
of
h
um
an
can
cers
[41,59,74,85].
Ph
arm
aceuticalin
h
ibitors
of
N
otch
sig-
n
allin
g
such
as
dem
cizum
ab
an
d
tarextum
ab
are
bein
g
actively
in
vestigated
as
n
ovelan
ti-can
cer
agen
ts
[64].
N
om
enclature
notch
1
notch
2
notch
3
notch
4
H
G
N
C
,U
niProt
N
O
TCH
1,P46531
N
O
TCH
2,Q
04721
N
O
TCH
3,Q
9U
M
47
N
O
TCH
4,Q
99466
C
om
m
ents
Various
types
ofactivating
and
inactivating
N
O
TC
H
1
m
utations
have
been
reported
to
be
associated
w
ith
hum
an
diseases,for
exam
ple:aortic
valve
disease
[23,52],Adam
s-O
liver
syndrom
e
5
[76],T-cellacute
lym
phoblastic
leukem
ia
(T-ALL)
[87],chronic
lym
phocytic
leukem
ia
(C
LL)
[65]and
head
and
neck
squam
ous
cellcarcinom
a
[1,77].
–
–
N
otch
4
is
a
potential
therapeutic
m
olecular
target
for
triple-negative
breast
cancer
[42,55].
Fu
rth
er
read
in
g
o
n
N
o
tch
recep
to
rs
Borggrefe
T
et
al.
(2016)
Th
e
N
otch
in
tracellular
dom
ain
in
tegrates
sign
als
from
W
n
t,H
edgeh
og,
TG
Fbeta/BM
P
an
d
h
ypoxia
path
w
ays.Biochim
Biophys
A
cta
1863
:303-313
[PM
ID
:26592459]
C
h
en
g
Y
L
et
al.
(2015)
Em
ergin
g
roles
of
th
e
gam
m
a-secretase-n
otch
axis
in
in
flam
m
ation
.
Phar-
m
acolT
her147
:80-90
[PM
ID
:25448038]
Palm
er
W
H
et
al.
(2015)
Ligan
d-In
depen
den
t
M
ech
an
ism
s
of
N
otch
A
ctivity.
Trends
C
ell
Biol25
:
697-707
[PM
ID
:26437585]
PrevisR
A
etal.(2015)M
olecularpath
w
ays:tran
slation
alan
d
th
erapeutic
im
plication
s
ofth
e
N
otch
sign
alin
g
path
w
ay
in
can
cer.C
lin
C
ancer
Res
21
:955-61
[PM
ID
:25388163]
Takebe
N
etal.(2015)Targetin
g
N
otch
,H
edgeh
og,an
d
W
n
tpath
w
ays
in
can
cer
stem
cells:clin
ical
update.N
atRev
C
lin
O
ncol12
:445-464
[PM
ID
:25850553]
Regulators
of
G
protein
Signaling
(RG
S)
proteins
O
th
er
protein
targets→
R
egulators
of
G
protein
Sign
alin
g
(R
G
S)
protein
s
O
verview
:
R
egulators
of
G
protein
sign
allin
g
(R
G
S)
protein
s
in
crease
th
e
deactivation
rates
of
G
protein
sign
allin
g
path
w
ays
th
rough
en
h
an
cin
g
th
e
G
TPase
activity
of
th
e
G
protein
alph
a
subun
it.
In
teraction
s
th
rough
protein
:protein
in
teraction
s
of
m
an
y
R
G
S
protein
s
h
ave
been
iden
tified
for
targets
oth
er
th
an
h
eterom
eric
G
protein
s.Th
e
20
R
G
S
protein
s
are
com
m
on
ly
divided
in
to
four
fam
ilies
(R
4,R
7,R
12
an
d
R
Z)
based
on
sequen
ce
an
d
dom
ain
h
om
ology.
D
escribed
h
ere
is
R
G
S4
for
w
h
ich
a
n
um
ber
of
ph
arm
acologicalin
h
ibitors
h
ave
been
described.
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N
om
enclature
regulator
ofG
-protein
signaling
4
H
G
N
C
,U
niProt
RG
S4,P49798
C
om
m
on
abreviation
RG
S4
Selective
inhibitors
RG
S4
inhibitor
11b
(pIC
50
7.8)
[83],C
C
G
-50014
(pIC
50
7.5)
[8,83],RG
S4
inhibitor
13
(pIC
50
7.3)
[83]
Fu
rth
er
read
in
g
o
n
R
G
S
p
ro
tein
s
Seth
akorn
N
et
al.
(2010)
N
on
-can
on
ical
fun
ction
s
of
R
G
S
protein
s.
C
ell
Signal
22
:
1274-81
[PM
ID
:20363320]
Sjogren
B
(2017)
Th
e
evolution
of
regulators
of
G
protein
sign
allin
g
protein
s
as
drug
targets
-
20
years
in
th
e
m
akin
g:IU
PH
A
R
R
eview
21.
Br
JPharm
acol174
:427-437
[PM
ID
:28098342]
Sjogren
B
etal.(2010)Th
in
kin
g
outside
ofth
e
"R
G
S
box":n
ew
approach
es
to
th
erapeutic
targetin
g
of
regulators
of
G
protein
sign
alin
g.
M
olPharm
acol78
:550-7
[PM
ID
:20664002]
Turn
er
EM
et
al.
(2012)
Sm
allM
olecule
In
h
ibitors
of
R
egulator
of
G
Protein
Sign
allin
g
(R
G
S)
Pro-
tein
s.A
C
S
M
ed
C
hem
Lett3
:146-150
[PM
ID
:22368763]
Sigm
a
receptors
O
th
er
protein
targets→
Sigm
a
receptors
O
verview
:
A
lth
ough
term
ed
‘receptors’,
th
e
eviden
ce
for
couplin
g
th
rough
con
ven
tion
al
sign
allin
g
path
w
ays
is
lackin
g.
In
itially
described
as
a
subtype
of
opioid
receptors,
th
ere
is
on
ly
a
m
odest
ph
arm
acologicaloverlap
an
d
n
o
structuralcon
vergen
ce
w
ith
th
e
G
protein
-coupled
receptors;th
e
crystalstructure
ofth
e
sigm
a1
receptor
[94]suggests
a
trim
eric
structure
ofa
sin
gle
sh
orttran
sm
em
bran
e
dom
ain
traversin
g
th
e
en
doplasm
ic
reticulum
m
em
bran
e,w
ith
th
e
bulk
of
th
e
protein
facin
g
th
e
cytosol.
A
w
ide
ran
ge
of
com
poun
ds,ran
gin
g
from
psych
oactive
agen
ts
to
an
tih
istam
in
es,
h
ave
been
observed
to
bin
d
to
th
ese
sites.
N
om
enclature
sigm
a
non-opioid
intracellular
receptor
1
σ
2
H
G
N
C
,U
niProt
SIG
M
AR1,Q
99720
–
Selective
agonists
PRE-084
[80],(+)-SKF
10.047
–
Selective
antagonists
N
E-100
(pIC
50
8.4)
[60],BD
-1047
(pIC
50
7.4)
[51]
–
Labelled
ligands
[ 3H
]pentazocine
(Agonist)
[ 3H
]-di-o-tolylguanidine
(Agonist)
C
o
m
m
en
ts:
(-)-pen
tazocin
e
also
sh
ow
s
activity
at
opioid
receptors.
Th
e
sigm
a2
receptor
h
as
recen
tly
been
reported
to
be
TM
EM
97
Q
5BJF2
[92]
,a
4TM
protein
partn
er
of
N
PC
1,th
e
N
iem
an
n
-Pick
C
1
protein
,a
13TM
ch
olesterol-bin
din
g
protein
.
Fu
rth
er
read
in
g
o
n
Sig
m
a
recep
to
rs
C
h
u
U
B
etal.(2016)Bioch
em
icalPh
arm
acology
ofth
e
Sigm
a-1
R
eceptor.M
olPharm
acol89
:142-53
[PM
ID
:26560551]
G
ris
G
et
al.
(2015)
Sigm
a-1
receptor
an
d
in
flam
m
atory
pain
.
Infl
am
m
Res
64
:
377-81
[PM
ID
:25902777]
R
ousseaux
C
G
et
al.
(2015)
Sigm
a
receptors
[sigm
aR
s]:
biology
in
n
orm
al
an
d
diseased
states.
J
ReceptSignalTransductRes
1-62
[PM
ID
:26056947]
Su
TP
et
al.
(2016)
Th
e
Sigm
a-1
R
eceptor
as
a
Pluripoten
t
M
odulator
in
Livin
g
System
s.
Trends
Pharm
acolSci37
:262-78
[PM
ID
:26869505]
van
W
aarde
A
et
al.
(2015)
Poten
tial
application
s
for
sigm
a
receptor
ligan
ds
in
can
cer
diagn
osis
an
d
th
erapy.Biochim
Biophys
A
cta
1848
:2703-14
[PM
ID
:25173780]
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Tubulins
O
th
er
protein
targets→
Tubulin
s
O
verview
:
Tubulin
s
are
a
fam
ily
of
in
tracellular
protein
s
m
ost
com
m
on
ly
associated
w
ith
m
icrotubules,
part
of
th
e
cytoskeleton
.
Th
ey
are
exploited
for
th
erapeutic
gain
in
can
cer
ch
em
oth
erapy
as
targets
for
agen
ts
derived
from
a
variety
of
n
aturalproducts:
taxan
es,colch
icin
e
an
d
vin
ca
alkaloids.
Th
ese
are
th
ough
t
to
act
prim
arily
th
rough
β-tubulin
,th
ereby
in
terferin
g
w
ith
th
e
n
orm
alprocesses
of
tubulin
polym
er
form
ation
an
d
disassem
bly.
N
om
enclature
tubulin
alpha
1a
tubulin
alpha
4a
tubulin
beta
class
I
tubulin
beta
3
class
III
tubulin
beta
4B
class
IVb
tubulin
beta
8
class
VIII
H
G
N
C
,
U
niProt
TU
BA1A,
Q
71U
36
TU
BA4A,
P68366
TU
BB,P07437
TU
BB3,Q
13509
TU
BB4B,P68371
TU
BB8,Q
3ZC
M
7
Inhibitors
–
–
vinblastine
(pIC
50
9),vincristine,eribulin
(pIC
50
8.2)
[58],paclitaxel(pEC
50
8.1)
[61],colchicine
(pIC
50
8)
[13],cabazitaxel,docetaxel,ixabepilone
com
bretastatin
A4
(pIC
50
8.2)
[22]
–
–
Fu
rth
er
read
in
g
o
n
T
u
b
u
lin
s
G
adadh
ar
S
etal.(2017)
Th
e
tubulin
code
at
a
glan
ce.
JC
ellSci130
:1347-1353
[PM
ID
:28325758]
Pen
n
a
LS
et
al.
(2017)
A
n
ti-m
itotic
agen
ts:
A
re
th
ey
em
ergin
g
m
olecules
for
can
cer
treatm
en
t?
Pharm
acolT
her173
:67-82
[PM
ID
:28174095]
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